CRISPR Therapeutics AG
CRSP
$54.13
-$0.19-0.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -208.55M | -136.00M | -37.31M | -85.94M | -126.41M |
| Total Depreciation and Amortization | 4.65M | 4.74M | 4.84M | 4.74M | 4.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.53M | 22.47M | 6.79M | 14.65M | 15.49M |
| Change in Net Operating Assets | -16.51M | 54.85M | -24.35M | -40.36M | 10.49M |
| Cash from Operations | -113.88M | -53.95M | -50.03M | -106.91M | -95.58M |
| Capital Expenditure | -117.00K | -206.00K | -254.00K | -219.00K | -707.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.09M | -19.55M | 106.08M | -161.39M | -126.20M |
| Cash from Investing | 69.98M | -19.76M | 105.83M | -161.60M | -126.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.26M | 10.59M | 16.88M | 9.64M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -466.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.26M | 10.59M | 16.88M | 9.64M | -466.00K |
| Foreign Exchange rate Adjustments | 80.00K | 41.00K | -87.00K | 75.00K | 2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -41.57M | -63.07M | 72.59M | -258.80M | -222.95M |